Green Cross Corp
006280
Company Profile
Business description
Green Cross Corp is one of the global leaders in the healthcare sector. The Montreal-based biopharmaceutical company primarily develops intravenous immunoglobulin (IVIG), a key therapeutic solution for the treatment of patients with infectious and immune diseases, and albumin, used as a blood-volumizing agent and in the treatment of burns. Currently, the company has a global presence through its association with various subsidiaries.
Contact
303 Bojeong-Dong
Giheung-Gu
YonginGyeonggi449-070
KORT: +82 312609300
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
2,276
Stocks News & Analysis
stocks
10 of the cheapest global companies with wide moats
These undervalued stocks of high-quality companies could be attractive investments today.
stocks
Bookworm: Buy and hold inspiration from an unlikely source
Ben Graham was the king of flipping deep value stocks. The best investment of his life came from something very different.
stocks
What next for the largest company on the ASX?
After a historic rally in 2024, what lies ahead for this overvalued banking titan?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,069.50 | 56.20 | 0.70% |
| CAC 40 | 8,028.28 | 90.07 | 1.13% |
| DAX 40 | 22,567.14 | 109.27 | -0.48% |
| Dow JONES (US) | 41,488.19 | 674.62 | 1.65% |
| FTSE 100 | 8,632.33 | 89.77 | 1.05% |
| HKSE | 23,959.98 | 497.33 | 2.12% |
| NASDAQ | 17,303.01 | 345.44 | -1.96% |
| Nikkei 225 | 37,519.24 | 466.14 | 1.26% |
| NZX 50 Index | 12,244.83 | 21.42 | -0.17% |
| S&P 500 | 5,638.94 | 117.42 | 2.13% |
| S&P/ASX 200 | 7,838.10 | 48.40 | 0.62% |
| SSE Composite Index | 3,419.56 | 0.00 | -0.00% |